Eribulin: all 134 studies that test it

Page 2 of 2. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast CancerCompletedNCT03583944Phase 4
• M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast CancerTerminatedNCT03579472Phase 1
• Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian CancerCompletedNCT03430518Phase 1
• A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and TaxanesStatus unknownNCT03412955Phase 2
• Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryActive, not recruitingNCT03361436Phase 1
• A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + TrastuzumabCompletedNCT03264547Phase 3
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT03237780Phase 2
• Study of E7389 Liposomal Formulation in Participants With Solid TumorActive, not recruitingNCT03207672Phase 1
• Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer PatientsWithdrawnNCT03032614Phase 2
• To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid TumorsCompletedNCT03002493Phase 1
• PAINTER: Polymorphism And INcidence of Toxicity in ERibulin TreatmentCompletedNCT02864030Phase 4
• Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast CancerTerminatedNCT02824575Phase 1
• PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)CompletedNCT02723877Phase 1/2
• Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast CancersStatus unknownNCT02616848Phase 1
• A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid TumorsCompletedNCT02596503Phase 1
• Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast CancerTerminatedNCT02404506Phase 2
• Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related CancersWithdrawnNCT02396433Phase 1/2
• Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain TumorsCompletedNCT02338037Early Phase 1
• Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast CancerCompletedNCT02263495Phase 2
• Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesCompletedNCT02225470Phase 3
• Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerWithdrawnNCT02215876Phase 2
• Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC PatientsStatus unknownNCT02175446Phase 2
• Study of Eribulin in Children With Cancer to Determine SafetyTerminatedNCT02082626Phase 1
• DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).CompletedNCT02035813Phase 2
• Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid TumorsCompletedNCT02014337Phase 1
• First Line Metastatic Breast Cancer Treatment (ESMERALDA)CompletedNCT01941407Phase 2
• A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast PatientsCompletedNCT01795586Phase 1
• Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast CancerCompletedNCT01669252Phase 2
• Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in CombinationCompletedNCT01585870Phase 1
• An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal FunctionCompletedNCT01418677Phase 1
• Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer PatientsStatus unknownNCT01372579Phase 2
• Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00415324Phase 1
• Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by SurgeryCompletedNCT00410553Phase 1
• E7389 in Treating Patients With Advanced Solid TumorsCompletedNCT00047034Phase 1

← Eribulin overview